Additionally, a Phase 2 open-label extension study evaluates long-term safety and efficacy of zasocitinib in 183 participants aged 1876 with both UC and CD who demonstrated clinical or symptomatic response at week 52 of their parent trials, focusing on treatment-emergent AEs and clinically significant changes in vital signs, laboratory values, and ECG over 108 weeks of continued treatment, having started in May 2025 with completion expected in December 2029 (NCT06764615)
Since then, the Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT) cardiovascular outcomes trial has shown that semaglutide 2.4 mg once weekly was associated with a significant 20% relative risk reduction in major cardiovascular adverse events compared with placebo [38]
prescription drug prices for Medicare to the world's cheapest price tags but was met with successful legal challenges from the pharmaceutical industry
Always coordinate medication changes, such as starting or stopping Ozempic, with your prescribing physician
Orders placed before 3pm are shipped the same day